Matthew Kulke

Matthew Kulke

Name	Matthew Kulke
Birth name
Birth date
Birth place
Death date
Death place
Alma mater
Occupation	Physician, Oncologist, Professor
Years active
Organization
Known for	Neuroendocrine Tumor Research
Notable works
Spouse(s)
Website

Matthew Kulke is a renowned American physician and oncologist, recognized for his significant contributions to the field of neuroendocrine tumors (NETs). He is a leading expert in the diagnosis and treatment of these rare and complex cancers, which arise from cells of the endocrine and nervous systems.

Early Life and Education

Matthew Kulke was born in the United States. He pursued his undergraduate studies at Harvard University, where he developed an early interest in medicine and oncology. He went on to earn his medical degree from University of California, San Francisco (UCSF) School of Medicine. Following medical school, Dr. Kulke completed his residency in internal medicine at Brigham and Women's Hospital in Boston, Massachusetts, and a fellowship in medical oncology at Dana-Farber Cancer Institute.

Career

Dr. Kulke has held several prestigious positions throughout his career. He served as the Director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute and was a Professor of Medicine at Harvard Medical School. In these roles, he led numerous clinical trials and research initiatives aimed at improving the understanding and treatment of neuroendocrine tumors.

In 2018, Dr. Kulke joined Boston University School of Medicine as the Chief of Hematology/Oncology and the Zoltan Kohn Professor of Medicine. At Boston University, he continues to advance research in neuroendocrine tumors and provides leadership in the field of oncology.

Research Contributions

Dr. Kulke's research has significantly advanced the understanding of neuroendocrine tumors. He has published extensively on the biology, diagnosis, and treatment of NETs, contributing to the development of new therapeutic strategies. His work has been instrumental in the approval of several new drugs for the treatment of neuroendocrine tumors, including everolimus and sunitinib.

Awards and Honors

Throughout his career, Dr. Kulke has received numerous awards and honors in recognition of his contributions to oncology and neuroendocrine tumor research. He is a member of several professional organizations, including the American Society of Clinical Oncology (ASCO) and the North American Neuroendocrine Tumor Society (NANETS).

Also see

• Neuroendocrine tumor
• Oncology
• Dana-Farber Cancer Institute
• Boston University School of Medicine

External links

• [Link to Matthew Kulke's profile at Boston University]
• [Link to publications by Matthew Kulke on PubMed]